New Survey Reveals That Low Sexual Desire Disrupts Relationships
Data show many women are not aware of hypoactive sexual desire disorder and
often blame themselves for symptoms of low desire
RED BANK, N.J., May 20, 2014
RED BANK, N.J., May 20, 2014 /PRNewswire/ -- Nearly one in two non-menopausal
women ages 30 to 50 say they have experienced low sexual desire at some point
in their lives, and many of these women (61%) felt distressed by it, according
to a new national survey.
Low sexual desire that is accompanied by distress and strains a woman's
relationship with her partner may be signs of a common type of female sexual
dysfunction known as hypoactive sexual desire disorder, or HSDD. Yet, while
most women were aware of erectile dysfunction and other men's sexual health
issues, only 14 percent of those surveyed, including women with symptoms of
low desire, were aware of HSDD, which has been a medical diagnosis for over 30
years. The survey, launched today as part of Women's Health Month, was
supported by HealthyWomen and Palatin Technologies, Inc., which is developing
an on-demand treatment for HSDD.
"Sex is an important part of a romantic relationship, so a lack of intimacy
can sometimes create tension within an otherwise healthy partnership," said
Beth Battaglino, R.N., CEO and President of HealthyWomen. "Women who avoid sex
because of low sexual desire may not realize that this could be a sign of a
medical issue. Most women don't know what female sexual dysfunction is nor do
they understand that conditions like HSDD are real and can be a serious
concern for them as well as their partner."
Indeed, most of the women surveyed said low sexual desire would hurt the level
of intimacy with their romantic partner (85%) and impair communication (66%).
Among those respondents who report experiencing low desire or who
self-identified with HSDD, nearly half (45%) blame themselves and 38 percent
admit that it makes them question their worth in the relationship.
Currently, there are no drugs in the United States approved for the treatment
of HSDD. According to the survey, most women (87%) believe there should be a
treatment available but are not aware of any treatment options for the
condition. More women would be interested in a treatment taken "on-demand" or
when needed for sexual activity as opposed to a daily pill (58% vs. 42%,
respectively). Among those who self-identified with HSDD, nearly all (92%)
said they would be interested in HSDD treatment; 75 percent said they are
frustrated that one is not yet available.
"It is important for women living with HSDD or some other form of female
sexual dysfunction to not blame themselves and feel confident to discuss their
concerns with their healthcare provider and their partner," Battaglino said.
"At HealthyWomen, we support the ongoing research in female sexual health
focused on providing women with access to safe and effective therapies."
About Female Sexual Dysfunction
Female sexual dysfunction (FSD) is often described as a disturbance in sexual
functioning. It is multidimensional and can be caused by physiological,
psychological, emotional and/or relational factors. FSD can have a major
impact on a woman's sexual relationships, interpersonal relationships, quality
of life and even their general well-being.
There are four main types of FSD: sexual desire disorders, female sexual
arousal disorder (FSAD), female orgasmic disorder (FOD) and sexual pain
disorders. One type of sexual desire disorder is hypoactive sexual desire
disorder (HSDD), the most common form of FSD.
HSDD is characterized by a lack of sexual thoughts and desire for sexual
activity, which causes a woman distress or puts a strain on the relationship
with her partner and cannot be accounted for by another medical, physical or
psychiatric condition or a substance-like medication. It is estimated that
one in 10 women may have signs of HSDD. There are no drugs in the United
States approved for the treatment of HSDD.
About the Survey
The survey was conducted by Ipsos North America, an independent market
research company, and supported by HealthyWomen and Palatin Technologies, Inc.
The 10-minute online survey was fielded from April 4 to 18, 2014 among a
representative sample of U.S. women ages 30 to 50 (n=1,028).Of these women,
906 self-identified as non-menopausal (have not yet experienced menopause or
are considered perimenopausal). The margin of error for U.S. non-menopausal
women ages 30 to 50 is +/-3.3%. If the study were replicated, the research
findings would not vary by more than 3.3 percentage points, respectively, in
either direction 95 times out of 100.
HealthyWomen (HW) is the nation's leading nonprofit health information source
for women. For 25 years, women have been coming to HW for answers to their
most pressing and personal health care questions. HW provides award-winning
health information through a wide array of online content and print
publications that are original, objective and reviewed and approved by medical
experts. Its HON-certified website, www.HealthyWomen.org®, has been recognized
by ForbesWoman as one of the "Top 100 Websites for Women" for the third year
in a row and was named the top women's health website by Dr. Mehmet Oz in O,
The Oprah Magazine. To learn more, visit www.HealthyWomen.org.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted,
receptor-specific peptide therapeutics for the treatment of diseases with
significant unmet medical need and commercial potential. Palatin's lead
compound under development is Bremelanotide, a first-in-class, investigative
melanocortin agonist being developed as an on-demand treatment for female
sexual dysfunction (FSD). Phase 3 clinical trials are anticipated to start in
the second half of calendar 2014. Palatin's strategy is to develop products
and then form marketing collaborations with industry leaders in order to
maximize their commercial potential. For additional information regarding
Palatin, please visit Palatin's website at http://www.palatin.com.
Statements in this press release that are not historical facts, including
statements about future expectations of Palatin Technologies, Inc. such as
statements about clinical trial results, potential actions by regulatory
agencies including the U.S. Food and Drug Administration (FDA), regulatory
plans, development programs, proposed indications for product candidates and
market potential for product candidates, are "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined in the
Private Securities Litigation Reform Act of 1995. Palatin intends that such
forward-looking statements be subject to the safe harbors created thereby.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors that could cause Palatin's actual results to be materially
different from its historical results or from any results expressed or implied
by such forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements for reasons
including, but not limited to, results of clinical trials, regulatory actions
by the FDA and the need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully complete clinical
trials, the length of time and cost required to complete clinical trials and
submit applications for regulatory approvals, products developed by competing
pharmaceutical, biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in Palatin's
periodic filings with the Securities and Exchange Commission. Palatin is not
responsible for updating for events that occur after the date of this press
Palatin Technologies Investor Inquiries:
Stephen T. Wills, CPA, MST
Chief Operating Officer / Chief Financial Officer
Tel: (609) 495-2200 / email@example.com
Palatin Technologies Media Inquiries:
Ogilvy Public Relations
Tel: (212) 880-5353 / firstname.lastname@example.org
Clayton A. Epidemiology and Neurobiology of Female Sexual Dysfunction.J Sex
Frank J, et al. Diagnosis and Treatment of Female Sexual Dysfunction.AmFam
Basson et al. Report of the International Consensus Development Conference
on Female Sexual Dysfunction: Definitions and Classifications. J. Urol. 2000
Vol. ;163:, 888-–893.
Frank J et al. Diagnosis and Treatment of Female Sexual Dysfunction.AmFam
Physician 2008; 77(5): 635-642.
Diagnostic and Statistical Manual of Mental Disorders.4th ed. Text
Revision. Washington, DC: American Psychiatric Association; 2000.
Shifren JL, Monz BU, Russo PA, et al. Obstet Gynecol. 2008;112(5):970-978.
SOURCE Palatin Technologies, Inc.
Press spacebar to pause and continue. Press esc to stop.